Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Fineline Cube Apr 4, 2026
Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Fineline Cube Apr 3, 2026
Company Deals Digital

Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform

Fineline Cube Apr 3, 2026
Company Deals

Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform

Fineline Cube Apr 3, 2026
Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Fineline Cube Apr 2, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Fineline Cube Apr 4, 2026
Company Drug

Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen

Fineline Cube Apr 4, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026

The Medical Products Administration of Guangdong Province (GDMPA) and Health Commission of Guangdong Province (GDHC)...

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026

Insight Lifetech, a Qiming Venture Partners‑backed innovative medical device manufacturer, has listed on the Shanghai...

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products...

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China’s largest pharmaceutical companies,...

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Fineline Cube Feb 6, 2026

Akeso, Inc. (HKG: 9926) announced that Yidafang (ivonescimab) has been awarded Breakthrough Therapy Designation (BTD)...

Company Drug

Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies

Fineline Cube Feb 6, 2026

Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China’s National Medical Products Administration...

Company Drug

HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients

Fineline Cube Feb 6, 2026

HighTide Therapeutics Inc. (HKG: 2511), the China‑based biopharmaceutical company, announced completion of the Phase IIb...

Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026

Knature Biopharmaceutical Co., Ltd., a China‑based biopharma specializing in mitochondrial medicine, has submitted its initial...

Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026

XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino‑US AI‑powered drug discovery platform, has entered a strategic...

Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026

The National Healthcare Security Administration (NHSA) issued a landmark notice this week to accelerate the...

Company Drug

J&J Darzalex Faspro Gets NMPA Approval for Transplant-Eligible Myeloma Patients

Fineline Cube Feb 6, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that Darzalex Faspro (daratumumab and hyaluronidase-fihj) has received National...

Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced plans to transfer its 30% equity...

Company Drug

Everest Medicines Files Velsipity for Ulcerative Colitis in China

Fineline Cube Feb 6, 2026

Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity...

Company

Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025

Fineline Cube Feb 6, 2026

Bristol-Myers Squibb (BMS, NYSE: BMY) reported fourth‑quarter 2025 revenue of USD 12.5 billion, up 1% year‑on‑year (YOY), while...

Company Drug

Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting

Fineline Cube Feb 6, 2026

Merck & Co. (MSD, NYSE: MRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval...

Policy / Regulatory

Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program

Fineline Cube Feb 6, 2026

The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening...

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Fineline Cube Feb 5, 2026

Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Fineline Cube Feb 5, 2026

Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026

Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug...

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Fineline Cube Feb 5, 2026

GE HealthCare (NASDAQ: GEHC) reported fourth‑quarter 2025 revenue of USD 5.7 billion, up 7.1% year‑on‑year (YOY), bringing full‑year...

Posts pagination

1 … 25 26 27 … 646

Recent updates

  • Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline
  • Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
  • Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline
  • Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen
  • Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Others

Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline

Company Drug

Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.